BrainSee

Patients

Important information to know

  1. It is important to understand that individuals diagnosed with amnestic mild cognitive impairment (aMCI) can experience one of two outcomes:
    • Remain stable or see an improvement
    • Progress to Alzheimer’s Disease (AD) Dementia 
  1. Please note that only your doctor can provide an accurate prognosis based on your unique condition. The BrainSee test serves as a valuable tool to help your doctor assess your condition more precisely. It provides reliable prognostic information to assist in creating the most effective treatment and care plans.

3.  Brain MRI is the key input requirement for BrainSee test. It’s important to know that MRI is safe and non-invasive and doesn’t involve radiation exposure or contrast injection, nor does it require any additional software or hardware for imaging centers. The MRI protocol is available both to your doctor and the imaging center.

4.  Before the FDA approval of BrainSee and market launch of the device, doctors can only offer statistical prognosis data. For instance, they might have told you that about 10-15% of patients with MCI progress to AD Dementia each year, reaching around 60% within five years.

5.  Soon after FDA approved of BrainSee, the device will be available and your doctor can provide a personalized prognosis, guiding you through subsequent steps to determine the best course of treatments for your specific situation.

6.  The primary goal for both your doctor and the BrainSee test will be to aid in navigating through your condition as early as possible. The intention is to delay the onset of Alzheimer’s Dementia. Remember, we’re in this journey together!

How to get a BrainSee test after it's FDA approved?

  1.  Talk to your doctor and ask them to arrange a BrainSee test for you. This involves adding you as a patient to the BrainSee platform, providing necessary information, requesting analysis, and then receiving the analysis report. The doctors who can request a BrainSee test for you include neurologists, geriatricians, primary care physicians, family doctors, and psychiatrists.
  2.  After discussing with your doctor, you will need to undergo a standard clinical brain MRI scan. Your doctor will prescribe this for you.
  3.  Once your MRI scan is complete, the files need to be uploaded to the BrainSee portal. This can be done in one of three ways:
    • (Recommended) You can bring your MRI scan files on a CD (or a memory flash drive) to your doctor’s office, where your doctor or their assistant will upload the files to the BrainSee portal.
    • Your doctor or their assistant can access your MRI files through their online portal with the imaging center and upload them to the BrainSee portal. 
    • The imaging center that performed your MRI can upload your images directly to the BrainSee portal.
  4.  Your doctor will also arrange for you to take two initial cognitive tests and will input the results into the BrainSee portal.
  5.  You’ll get an email from the BrainSee portal to make a payment for the BrainSee test.
  6.  Once all these steps are complete, your doctor will receive the BrainSee analysis report. They will then be able to discuss the results with you and talk about what to do next.

Clinical Workflow Summary

How BrainSee Will Establish The Standard Of Care For Mild Cognitive Impairment

Alzheimer’s disease starts in the brain long before the onset of dementia, and can pass through a mild cognitive impairment stage on its way to dementia stage. Mild cognitive impairment is a gray zone, which is neither cognitively normal nor full blown dementia.

Amnestic Mild cognitive impairment (aMCI) is a type of MCI where memory loss is an outstanding concern. aMCI is a condition that can be caused by Alzheimer’s disease, normal aging, or other neurological conditions. A third of aMCI patients will stay stable or even improve in time and therefore will never get to dementia stage. These aMCI patients do not have Alzheimer’s disease and their condition is caused by other factors.

Today, it’s not possible to clinically differentiate aMCI caused by Alzheimer’s disease from aMCI caused by non-Alzheimer etiologies. BrainSee helps doctors make such a differentiation (prognosis of aMCI).

Early rule-out of Alzheimer’s disease, enabled by BrainSee, helps relieve the tremendous anxiety in aMCI patients and their family members. It also helps them avoid unnecessary expensive, invasive, and inconclusive alternative tests. 

Early detection of Alzheimer’s disease, enabled by BrainSee, can help postpone dementia through:

  • early interventions (medications and lifestyle changes)
  • better management of comorbidities
Early identification of Alzheimer’s disease also enables patients and their families to make practical plans for their upcoming legal and financial needs and determine best opportunities for care options.

BrainSee score is dynamic and patient-specific. Changes in such a granular quantitative measure of the brain can help doctors find the best course of interventions for their patients. It can also be used in clinical trials that aim to prevent / postpone dementia. 

Clinical course of Alzheimer’s disease

Normal cognition

Mild Cognitive Impairment

Time of clinical diagnosis using BrainSee as an aid

- Interventions are feasible
- A short, easy, and convenient process for patients (all non-invasive)

Dementia

Current time of clinical diagnosis

- Too late to intervene effectively.
- A long, complicated process for patients (sometimes even invasive)